Pipeline Overview
Four development pillars
A pipeline spanning obesity therapeutics, delivery, half-life extension, and oncology adjuncts, with near-term work focused on staged experimental de-risking.
PipelineObjectiveCurrent StageNear-Term Milestones
Lead obesity therapeuticNon-GLP-1-based modular obesity platform centred on a compact linear peptide fewer than 40 amino acids long, designed around four obesity-relevant receptor systems and intended to support standalone or co-administration development strategies.AI-guided in-silico candidate generation completedFinal candidate shortlist, synthesis, receptor pharmacology, first in vitro assays, early biological validation, and half-life extension integration.
Transdermal obesity delivery platformA third delivery option between needle pens and oral GLP-1 receptor agonists.CSIRO feasibility completedTarget product profile, proof-of-concept design, in vitro and ex vivo delivery studies.
Half-life extension technologiesApproaches to improve exposure duration, receptor engagement pattern, pharmacodynamic durability, dosing convenience, and long-term performance.Design-stage developmentSelection of preferred approaches, candidate pairing, in vitro stability, and PK planning.
Oncology adjunct conjugatesAdjunct conjugates targeting the tumour microenvironment and chemotherapy side effects.Early discoveryTarget selection, conjugate design, proof-of-concept assays, and partnership planning.